Steady‐State Pharmacokinetics and Dose Proportionality of Troglitazone and Its Metabolites
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
This study evaluated the steady‐state pharmacokinetics and dose proportionality of troglitazone, metabolite 1 (sulfate conjugate), and metabolite 3 (quinone metabolite) following administration of daily oral doses of 200, 400, and 600 mg troglitazone for 7 days (per dosing period) to 21 subjects. During each dosing period, plasma samples were collected predose on days 1, 5, 6, and 7 and serially for 24 hours on day 7. Steady‐state plasma concentrations for troglitazone, metabolite 1, and metabolite 3 were achieved by day 7. Troglitazone was rapidly absorbed with mean tmax values of 2.7 to 2.9 hours. Mean Cmax and AUC(0–24) values for troglitazone, metabolite 1, and metabolite 3 increased proportionally with increasing troglitazone doses over the clinical dose range of 200 mg to 600 mg administered once daily. Mean troglitazone CL/F, percent fluctuation, and AUC ratios of metabolite 1 and metabolite 3 to troglitazone were similar across dose groups. These data suggest that the pharmacokinetics and disposition of troglitazone and its metabolites are independent of dose over the dose range studied. Thus, troglitazone, metabolite 1, and metabolite 3 displayed linear pharmacokinetics at steady‐state.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bailey, C. J., & Turner, R. C. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602293340906 · Cited by 1,726
Cited by
Hewitt, N. J., Gómez Lechón, M. J., Houston, J. B., Hallifax, D., Brown, H. S., Maurel, P., Kenna, J. G., Gustavsson, L., Lohmann, C., Skonberg, C., et al. (2007) · Drug Metabolism Reviews · doi:10.1080/03602530601093489 · Cited by 735
“In humans, troglitazone is predominantly conjugated with sulfate (70% of all metabolites (Loi et al., 1999a,b) and only 3% of orally administered troglitazone is excreted unchanged in the urine.”
BackgroundSwift*, B., Pfeifer*, N. D., & Brouwer, K. L. R. (2010) · Drug Metabolism Reviews · doi:10.3109/03602530903491881 · Cited by 365
Bell, C. C., Dankers, A. C. A., Lauschke, V. M., Sison-Young, R., Jenkins, R., Rowe, C., Goldring, C. E., Park, K., Regan, S. L., Walker, T., et al. (2018) · Toxicological Sciences · doi:10.1093/toxsci/kfx289 · Cited by 327
Drug Bioactivation Covalent Binding to Target Proteins and Toxicity Relevance
Zhou, S., Chan, E., Duan, W., Huang, M., & Chen, Y.-Z. (2005) · Drug Metabolism Reviews · doi:10.1081/dmr-200028812 · Cited by 274
Bell, C. C., Lauschke, V. M., Vorrink, S. U., Palmgren, H., Duffin, R., Andersson, T. B., & Ingelman-Sundberg, M. (2017) · Drug Metabolism and Disposition · doi:10.1124/dmd.116.074369 · Cited by 201
“…troglitazone toxicity at clinically relevant concentrations, with IC 50 values in PHH spheroids reaching therapeutic levels after chronic exposures (14-day IC 50 = 1.5 m M for PHHs, 34.6 m M for HepaRG cells, and 18.7 m M for hiPS-Hep cells; therapeutic C max = 2.82 m M; Loi et al., 1999).”
BackgroundInfluential
Metadata
- Authors
- Loi, C., Alvey, C. W., Vassos, A. B., Randinitis, E. J., Sedman, A. J., & Koup, J. R.
- Venue
- The Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 1999-09
- Volume
- 39
- Issue
- 9
- Pages
- 920-926
- ISSN
- 0021-9754 (ISSN-L)
- 0091-2700
- 1552-4604
- OpenAlex
- W2061699782
- Cited by
- 53
- References
- 1
- FWCI
- 2.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Steady‐State Pharmacokinetics and Dose Proportionality of Troglitazone and Its Metabolites. https://app.cochat.ai/papers/10.1177/00912709922008533
- The paper
- Loi, C., Alvey, C. W., Vassos, A. B., Randinitis, E. J., Sedman, A. J., & Koup, J. R. (1999). Steady‐State Pharmacokinetics and Dose Proportionality of Troglitazone and Its Metabolites. The Journal of Clinical Pharmacology. https://doi.org/10.1177/00912709922008533
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.